ArticleBMC clinical pathology2009
CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.
Article in BMC clinical pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- AMEND 2.0: module identification and multi-omic data integration with multiplex-heterogeneous graphs.BMC bioinformatics · 2025Article
- An information theoretic approach to detecting spatially varying genes.Cell reports methods · 2023Article
- Cancer Vaccines, Adjuvants, and Delivery Systems.Frontiers in immunology · 2021Review
- Prognostic Value of Vimentin Is Associated With Immunosuppression in Metastatic Renal Cell Carcinoma.Frontiers in oncology · 2020Article
- The different expression of glycogen phosphorylases in renal clear cell renal carcinoma and chromophobe renal carcinoma.Clinical proteomics · 2020Article
- Vimentin Overexpressions Induced by Cell Hypoxia Promote Vasculogenic Mimicry by Renal Cell Carcinoma Cells.BioMed research international · 2019Article
- Vimentin Diversity in Health and Disease.Cells · 2018Review
- Key miRNAs and target genes played roles in the development of clear cell renal cell carcinoma.Cancer biomarkers : section A of Disease markers · 2018Article
- The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma.EXCLI journal · 2017Article
- Selected tumor markers in the routine diagnosis of chromophobe renal cell carcinoma.Archives of medical science : AMS · 2016Article
- Article
- Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.BioTechniques · 2016Article
- Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2015Article
- Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies.Oncoscience · 2015Review
- Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4.Cancer research · 2014Article
- DNA-aptamer targeting vimentin for tumor therapy in vivo.Nucleic acid therapeutics · 2014Article
- Oncogenic micro-RNAs and Renal Cell Carcinoma.Frontiers in oncology · 2014Review
- Tumor suppressive microRNA‑138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.International journal of oncology · 2012Article
- Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines.Molecular carcinogenesis · 2012Article
- Vimentin in cancer and its potential as a molecular target for cancer therapy.Cellular and molecular life sciences : CMLS · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) and chromophobe renal cell carcinoma (chRCC) can usually be distinguished by histologic characteristics. Occasionally, diagnosis proves challenging and diagnostic difficulty will likely increase as needle biopsies of renal lesions become more common.
methodsTo identify markers that aid in differentiating ccRCC from chRCC, we used gene expression profiles to identify candidate markers that correlate with histology. 39 antisera and antibodies, including 35 for transcripts identified from gene expression profiling, were evaluated. Promising markers were tested on a tissue microarray (TMA) containing 428 renal neoplasms. Strength of staining of each core on the TMA was formally scored and the distribution of staining across different types of renal neoplasms was analyzed.
resultsBased on results from initial immunohistochemical staining of multitissue titer arrays, 23 of the antisera and antibodies were selected for staining of the TMA. For 7 of these markers, strength of staining of each core on the TMA was formally scored. Vimentin (positive in ccRCC) and CD9 (positive in chRCC) best distinguished ccRCC from chRCC. The combination of vimentin negativity and CD9 positivity was found to distinguish chRCC from ccRCC with a sensitivity of 100.0% and a specificity of 95.2%.
conclusionBased on gene expression analysis, we identify CD9 and vimentin as candidate markers for distinguishing between ccRCC and chRCC. In difficult cases and particularly when the amount of diagnostic tissue is limited, vimentin and CD9 staining could serve as a useful adjunct in the differential diagnosis of ccRCC and chRCC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.